BioCentury | Dec 19, 2020
Regulation

U.K. selects first drugs for pathfinding antimicrobial resistance initiative

The U.K. continues to be a leader in combatting what could be the next pandemic — one brought on by the failure of the market for antimicrobials. On Friday, NHS England and NHS Improvement selected the...
BioCentury | Nov 6, 2020
Management Tracks

BeiGene’s pathfinding CFO Liang to retire

Howard Liang, who has played an integral role in bringing global prominence to the China biotech sector over the past five years, is retiring as BeiGene CFO and chief strategy officer. The news came as...
BioCentury | Sep 7, 2020
Product Development

Back to School 2020: The imperative of COVID-19 — biopharma’s once-in-a-generation chance for change

2020 has handed biopharma an uncommon privilege: sitting at the eye of the storm, the industry has been tasked with stopping the COVID-19 pandemic that has brought the world to its knees. To have the...
BioCentury | Dec 10, 2019
Clinical News

Dec. 9 ASH Quick Takes: Kite, Principia, Blueprint, Precision and Rocket

...to FDA in the indication in 1Q20, when it expects data from the Phase II PATHFINDER...
BioCentury | Oct 17, 2019
Product Development

Horizon 2020’s successor aims for improved uptake of innovation

...the Pathfinder and the Accelerator -- to support early and late-stage product development, respectively. The Pathfinder...
BioCentury | Jun 13, 2019
Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

...$76 million series B round from investors who are banking on the potential of its PathFinder...
...Venture Partners, Biomatics Capital, GV, Johnson & Johnson Innovation -- JJDC Inc. and Mercury Fund. PathFinder...
...treating neurobehavioral disorders by targeting dysregulated neural circuits underlying specific symptoms (see “Circuit Logic” ). PathFinder...
BioCentury | Mar 14, 2019
Company News

Germany strikes outcomes-based deal with Novartis for Kymriah

CAR T therapy Kymriah tisagenlecleucel will be available in Germany under an outcomes-based payment model, the country's first such agreement for a gene or CAR T cell therapy. Novartis AG (NYSE:NVS; SIX:NOVN) and German health...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

...on improved health may carry over from the immediate to the long term. J&J, the pathfinder...
BioCentury | Jul 13, 2018
Company News

Kymriah deal to stay despite CMS shift on proposed pilot

Novartis AG (NYSE:NVS; SIX:NOVN) said on July 9 an outcomes-based contract for Kymriah tisagenlecleucel remains in effect with treatment centers. The contract is unaffected by CMS's decision not to pursue the pharma's proposal for a...
BioCentury | Jul 9, 2018
Politics & Policy

Kymriah deal to stay despite CMS shift on proposed pilot

Novartis AG (NYSE:NVS; SIX:NOVN) said Monday an outcomes-based contract for Kymriah tisagenlecleucel remains in effect with treatment centers. The contract is unaffected by CMS's decision not to pursue the pharma's proposal for a demonstration program...
Items per page:
1 - 10 of 63
BioCentury | Dec 19, 2020
Regulation

U.K. selects first drugs for pathfinding antimicrobial resistance initiative

The U.K. continues to be a leader in combatting what could be the next pandemic — one brought on by the failure of the market for antimicrobials. On Friday, NHS England and NHS Improvement selected the...
BioCentury | Nov 6, 2020
Management Tracks

BeiGene’s pathfinding CFO Liang to retire

Howard Liang, who has played an integral role in bringing global prominence to the China biotech sector over the past five years, is retiring as BeiGene CFO and chief strategy officer. The news came as...
BioCentury | Sep 7, 2020
Product Development

Back to School 2020: The imperative of COVID-19 — biopharma’s once-in-a-generation chance for change

2020 has handed biopharma an uncommon privilege: sitting at the eye of the storm, the industry has been tasked with stopping the COVID-19 pandemic that has brought the world to its knees. To have the...
BioCentury | Dec 10, 2019
Clinical News

Dec. 9 ASH Quick Takes: Kite, Principia, Blueprint, Precision and Rocket

...to FDA in the indication in 1Q20, when it expects data from the Phase II PATHFINDER...
BioCentury | Oct 17, 2019
Product Development

Horizon 2020’s successor aims for improved uptake of innovation

...the Pathfinder and the Accelerator -- to support early and late-stage product development, respectively. The Pathfinder...
BioCentury | Jun 13, 2019
Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

...$76 million series B round from investors who are banking on the potential of its PathFinder...
...Venture Partners, Biomatics Capital, GV, Johnson & Johnson Innovation -- JJDC Inc. and Mercury Fund. PathFinder...
...treating neurobehavioral disorders by targeting dysregulated neural circuits underlying specific symptoms (see “Circuit Logic” ). PathFinder...
BioCentury | Mar 14, 2019
Company News

Germany strikes outcomes-based deal with Novartis for Kymriah

CAR T therapy Kymriah tisagenlecleucel will be available in Germany under an outcomes-based payment model, the country's first such agreement for a gene or CAR T cell therapy. Novartis AG (NYSE:NVS; SIX:NOVN) and German health...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

...on improved health may carry over from the immediate to the long term. J&J, the pathfinder...
BioCentury | Jul 13, 2018
Company News

Kymriah deal to stay despite CMS shift on proposed pilot

Novartis AG (NYSE:NVS; SIX:NOVN) said on July 9 an outcomes-based contract for Kymriah tisagenlecleucel remains in effect with treatment centers. The contract is unaffected by CMS's decision not to pursue the pharma's proposal for a...
BioCentury | Jul 9, 2018
Politics & Policy

Kymriah deal to stay despite CMS shift on proposed pilot

Novartis AG (NYSE:NVS; SIX:NOVN) said Monday an outcomes-based contract for Kymriah tisagenlecleucel remains in effect with treatment centers. The contract is unaffected by CMS's decision not to pursue the pharma's proposal for a demonstration program...
Items per page:
1 - 10 of 63